Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probenecid in CPPD
NCT02243631Phase 1Completed
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2014
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of probenecid in calcium pyrophosphate deposition disease (CPPD) (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: ATP Levels in Synovial Fluid at 5 days. Started Oct 2014; status: completed.
02
Drugs
probenecid
03
Conditions
calcium pyrophosphate deposition disease (CPPD)
Beyond the preview
Go deeper on NCT02243631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243631.